Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer

PR Newswire February 4, 2014

Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH

Canada NewsWire February 3, 2014

Glu Mobile Adds an Arsenal of New Titles to Give 'Deer Hunter' Company: Glu Mobile Inc. (NASDAQ: GLUU), Aeterna Zentaris Inc. (NASDAQ: AEZS), Vical Inc. (NASDAQ:VICL), Delcath Systems Inc. (NASDAQ: DCTH)

Accesswire January 28, 2014

Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants

Canada NewsWire January 14, 2014

Aeterna Zentaris (T.AEZ) puts a price on offering and shares fall 18%

Gaalen Engen January 9, 2014

Aeterna Zentaris Announces Pricing of US$13.2 Million Public Offering of Common Shares and Warrants

Canada NewsWire January 9, 2014

Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants

Canada NewsWire January 8, 2014

Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA

Canada NewsWire January 6, 2014

Aeterna Zentaris Appoints Dr. Richard Sachse as Chief Scientific Officer

Canada NewsWire January 3, 2014

Aeterna Zentaris Announces Closing of US$15.1 Million Public Offering of Common Shares and Warrants

Canada NewsWire November 25, 2013

Five Star Equities Issues New Research Reports on AEZS, OXBT, UNIS and ZHNE

Accesswire November 21, 2013

TrendingWallStreet.com Releases Market Alerts on VJET, FNMA, VPCO, and AEZS

Accesswire November 21, 2013

SGOC, UNIS, AEZS and NWBO added to NASDAQ Active Stock Watch List at GSR

Accesswire November 20, 2013

Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants

Canada NewsWire November 19, 2013

Aeterna Zentaris Submits New Drug Application to FDA for Macimorelin Acetate (AEZS-130) for Evaluation of AGHD

Canada NewsWire November 5, 2013

Aeterna Zentaris Appoints Chief Commercial Officer, Reaffirming New Company Vision

Canada NewsWire November 1, 2013

Aeterna Zentaris to Announce Third Quarter 2013 Financial and Operating Results on November 5, 2013

Canada NewsWire October 29, 2013

Aeterna Zentaris Completes Successful Transfer of Cetrotide® Manufacturing Rights to Merck KGaA

Canada NewsWire October 1, 2013

Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York

Canada NewsWire August 29, 2013

Aeterna Zentaris Announces Listing Transfer to NASDAQ Capital Market

Canada NewsWire August 28, 2013